palonosetron

Known as: (3aS)-2-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-2,3,3a, 4,5,6-hexahydro-1H-benz[de]isoquinolin-1-one, Palonosetronum, palonosetron [Chemical/Ingredient] 
The active ingredient in a drug used to treat nausea and vomiting caused by cancer treatment. Palonosetron is a type of serotonin receptor antagonist… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
BACKGROUND NEPA is a novel oral fixed-dose combination of netupitant (NETU), a new highly selective neurokinin-1 (NK1) receptor… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Antiemetic guidelines recommend co-administration of agents that target multiple molecular pathways involved in emesis… (More)
  • figure 1
  • figure 3
  • table 1
  • table 3
  • table 2
Is this relevant?
2011
2011
Nausea and vomiting are among the major problems occurring during and after the chemotherapy treatments of cancer patients. The… (More)
  • table 1
  • table 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Palonosetron is a 5-HT(3) receptor antagonist that has demonstrated superiority in preventing both acute and delayed emesis when… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND Palonosetron is a second-generation 5-hydroxytryptamine 3 (5-HT(3))-receptor antagonist that has shown better efficacy… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2008
Highly Cited
2008
BACKGROUND We designed this multicenter, randomized, double-blind study to assess the efficacy and safety of three doses of… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2006
Highly Cited
2006
BACKGROUND This pivotal phase III trial evaluated the efficacy and safety of palonosetron in preventing acute and delayed… (More)
  • table 1
  • table 2
  • figure 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Palonosetron (Aloxi, Onicit) is a selective 5-HT(3) receptor antagonist recently approved by the Food and Drug Administration for… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
BACKGROUND Although all first-generation 5-HT(3) receptor antagonists demonstrate efficacy in preventing acute chemotherapy… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
BACKGROUND Palonosetron, a highly selective and potent 5-HT(3) receptor antagonist with a strong binding affinity and a long… (More)
Is this relevant?